Participated · Series B · Nov 2021

PathologyWatch operates an end-to-end digital dermatopathology platform that integrates laboratory information systems, scanners, a digital viewer, and EMR reporting to give clinics 24/7 access to digital slides and expert dermatopathologists. The company’s core product streamlines workflows for dermatology clinics and labs, enabling faster diagnoses and broader insurance coverage. PathologyWatch is positioning its platform to improve access and equity in dermatopathology while reducing pathology costs. With the new funding, the company plans further research into skincare diagnostics and AI to enhance its diagnostic capabilities. PathologyWatch is expanding operations nationwide and will add new labs in Texas, Florida, and Arizona to support growing volume. CEO and cofounder Dan Lambert emphasizes the company’s role in digitally transforming dermatopathology and improving patient care. PathologyWatch is a Salt Lake City, UT‑based provider of digital dermatopathology services that offers fully interfaced EMR reporting and around‑the‑clock access to digital slides. The company’s solution gives dermatology clinics, hospitals and laboratories access to top‑tier dermatopathologists and a streamlined clinical workflow that interfaces directly into the EMR. PathologyWatch aims to improve operational efficiency by speeding up workflow and enhance patient outcomes via its expert professional team and partner laboratory services. Led by CEO and co‑founder Dan Lambert, the company has raised over $10M in total capital to date. PathologyWatch plans to use new funding to develop its digital dermatopathology offerings, scale its laboratory system and extend artificial intelligence research across various cancer lines to support larger clients and further technological progress. PathologyWatch builds intuitive, easy‑to‑implement digital dermatopathology solutions that digitize pathology workflows and provide EMR‑integrated reporting and 24/7 access to digital slides. The company offers access to top dermatopathologists and lets clients interpret and bill for cases, with a primary focus on outpatient clinics. PathologyWatch has deployed supervised AI in dermatopathology and reports a live clinical implementation in Australia that can generate full reports. It will use the Series A proceeds to strengthen outreach to dermatology clinics nationwide, including plans to triple its sales force over 12 months, expand marketing, and implement a channel partner strategy. The funding will also support continued development of technology and supervised AI for various cancer lines.

Participated · Seed · Jun 2017

Blue Mesa Health offers a year-long, CDC-based digital diabetes prevention program that pairs dedicated health coaches with wireless scales and FitBit devices to drive behavior change. The company partners with doctors and risk-bearers (self-insured employers, health plans, ACOs, and hospital systems) and operates on a pay-for-performance model where it is paid when participants engage and lose weight. Blue Mesa runs three tailored programs—Transform (mobile cohort-based), Transformemos (Spanish-language), and Transform-By-Mail (low-tech phone/mail delivery)—to reach users across languages and technology levels. The team reports strong outcomes: 78% of participants reach 5.2% body weight loss at six months. In the near term they expect to help over 2,500 people reduce diabetes risk and plan to expand the program to 5,000 more participants and to additional countries. The company is fundraising to support that growth and anticipates pursuing a Series A within the year.

Led · Seed · Apr 2016

MedPilot builds a patient financial relationship platform that transforms patient billing through customized outreach tailored to patients’ communication preferences. The platform leverages emails, texts, calls, and statements and uses machine learning to optimize outreach based on patient interactions. It supplies tools for healthcare providers’ billing departments and revenue cycle management companies to track patients, manage experience, and monitor financial activity. MedPilot has helped over 1 million patients to date and reports a 97% patient satisfaction score. The company says it will use new funding to fuel its next stage of growth and continue modernizing the patient billing experience. MedPilot provides a patient financial engagement platform used by outpatient facilities, hospitals, revenue cycle management companies, and practice management systems. The platform combines millions of data points from clients' practice management systems with internally derived insights and analytics to personalize communication method, content, and payment options. Using machine learning, MedPilot continuously optimizes outreach strategies based on patient interactions and also provides administrative tools to track patients, manage experience, and monitor financial activity. The company is led by co-founder and CEO Jacob Myers and COO Nathan Spoden and is based in Cleveland, Ohio. MedPilot graduated in the latest class of the Cedars-Sinai Accelerator. It completed a $1.7M seed funding round to bolster the team and launch new functionality to further engage patients throughout their lifecycle. MedPilot provides a performance-analytics platform that gives healthcare providers insight into the most effective billing and collections outreach by tracking sent rate, open rate, click rate, and response time. The software uses patient demographics, payment history and behavioral-economics data to craft tailored payment-resolution strategies and optimize outreach content. It integrates with providers’ internal billing and collections teams and also collaborates with third-party collectors such as Retrieval Masters Creditors Bureau. The company says it will use new funding to invest in technology, sales and marketing, and to support operational costs. Co-founder Matthew Buder Shapiro has a background in digital marketing and emphasized allocating manual touch where needed and digital approaches where effective. MedPilot participated in Blueprint Health’s accelerator and is based in New York. The company raised $750,000 in a Seed round to support these plans.

Led · Seed · Jul 2015

iMedicare offers an application that monitors patients' health, compares health insurance plans, and provides alternative therapeutic options to improve care or reduce costs. The startup was founded in 2012 by Flaviu Simihaian and Matthew Johnson and built its early foundations in Charlotte, North Carolina. It operates offices in Cluj (six product-development employees) and New York (20 employees, mostly sales). The company has sold its solution to about 4,000 of the roughly 60,000 U.S. pharmacies, gaining a meaningful early market share. iMedicare reached profitability soon after its seed financing and has not needed additional funding to date. The firm plans to expand its pharmacy contracts to 10,000 by the end of the year and may consider outside investment for future expansion.

Led · Equity · Aug 2012

Symcat is an online symptom-based, computer-assisted triage tool that asks users about symptoms, age, gender and medical history, then compares inputs to CDC biosurveillance data and AHRQ guidelines to produce probable diagnoses and care recommendations. The product emphasizes concise, actionable guidance rather than encyclopedic content. Founders Craig Monsen and David Do (joined by Tolu Babalola) began conceptualizing the project in June 2011 and released a first prototype in November 2011; the team works out of the Butchers Hill neighborhood. Monsen and Do paused medical school to focus full-time on Symcat for a period and plan to continue developing the product while finishing their residency training. Symcat has participated in the Blueprint Health accelerator and has received grant support from the Robert Wood Johnson Foundation. Financially, known funding includes accelerator seed funding and a foundation award, which the team says helped with mentorship and product feedback.